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Abstract:  Psychiatric illness and epilepsy commonly co-occur in adults and in children and 
adolescents.  Theories of comorbidity are complex, but recurring associations between the 
conditions suggest overlap that is more than simple co-occurrence.  Common underlying 
pathophysiology may imply that epilepsy itself may constituently include psychiatric symptoms.  
Conditions such as depression or cognitive difficulties commonly occur and in some cases are 
considered to be associated with specific epilepsy characteristics such as localization or seizure 
type.  Regardless of etiologic attributions to psychiatric comorbidity, it is clear today that 
treatment for epilepsy needs to target psychiatric illness.  In many cases, quality of life 
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Introduction 
Psychiatric comorbidities have long been studied in the context of epilepsy.   A sizeable body of 
evidence supports the understanding that psychiatric illness is overrepresented in epilepsy as compared 
to other chronic medical illnesses (1).  Even with the markedly altered functionality and lifestyle 
associated with conditions such as cancer, diabetes, or asthma, the presence of psychiatric comorbidity 
in epilepsy appears to be more substantial (2).  Although opinions regarding the best methods of 
diagnostic assessment may differ, comparable assessment tools clearly find that the overrepresentation 
of psychiatric illness is significant both in adults and in pediatrics (3, 4).   
Nevertheless, a persisting challenge is in measuring the presence of comorbidity independent of 
possible confounding factors.  Very few studies assessing comorbidity are prospective in nature or have 
a population based approach.  Additionally, the broad spectrum of illness makes it difficult to isolate 
psychiatric symptoms from underlying medical or neurologic illness.  The epilepsy population itself is 
heterogeneous, so overlap with heterogeneous and somewhat arbitrarily categorized psychiatric 
conditions may hinder a comprehensive diagnostic approach.  Still, even with these challenges, the 
connection between psychiatric illness and epilepsy is abundantly present, especially for mood disorders 
and problems of cognition.       
What remains unclear is how epilepsy related characteristics may be etiologically associated 
with psychiatric comorbidity.  While it has been long considered intuitive that the more severe the 
epilepsy, the more severe the comorbidity, this may not be completely accurate.  It may be that specific 
seizure related characteristics affect the presence or absence of comorbidity.  Seizure frequency is 
commonly viewed as adversely impacting psychiatric state, as is the usage of multiple anticonvulsant 
medications, thus adding to the potential risk of developing psychiatric illness.  However, neither 
context may represent the essence of comorbidity in the truest sense.  
Ultimately, it may be that epilepsy is a broad spectrum illness with heterogeneity that includes 
psychiatric aspects.  In that sense, thinking of comorbidity as the association of two etiologically 
unrelated conditions would be inaccurate.  Certain types of epilepsies could have psychiatric, cognitive 
or behavioral complications that are inherently associated with a common underlying pathophysiology.  
With that approach, comorbidity would not exist; instead, the associated behavioral symptoms would 
be viewed simply as constituent parts of the epilepsy.   
Such a paradigm shift has marked implications in terms of treatment.  Despite the intrigue in 
thinking of comorbidity in this manner, it is a modern approach, and as such the evidence base for 
treatment is underdeveloped.  Treatment studies and clinical trials are not typically conceptualized in 
this way.   However it seems clearer now that in order to comprehensively treat epilepsy and to improve 
quality of life, both behavioral and seizure specific outcomes need to be addressed.   Even though this 
paradigm does not reflect the state of the evidence at this time, the approach of identifying psychiatric 
symptoms independently is still meaningful as a first step in management.  The evidence base does help 
us in that regard, and will be reviewed in the following sections. 
COMMON COMORBIDITIES IN ADULTS 
Epidemiological aspects in adults with epilepsy 
Mood disorders 
 Cross-sectional, population-based studies in adults with epilepsy are showing a uniformly 
increased prevalence of depression, with prevalence rates very similar to those of the general 
population only among seizure free patients (5), while the prevalence is definitely higher than that in 
unselected samples (between 17% and 22%) (6), and it is up to 55% in patients with drug-resistant 
epilepsy (7). In general terms, these figures partially reflect the severity of the underlying seizure 
disorder not only in terms of psychosocial difficulties but also in terms of brain dysfunction. Cross-
sectional studies are highly informative from a public health perspective, as they give an idea of the size 
of the problem, but cohort studies can provide information on the temporal relationship between 
comorbid conditions. In fact, a number of studies are now suggesting that the relationship between 
epilepsy and depression is not necessarily unidirectional and patients with depression are at increased 
risk of developing epilepsy as well.  Data from the UK General Practice Research Database show that the 
incidence-rate ratio of depression is significantly higher during the three years preceding the onset of 
epilepsy (8). A study from Sweden shows that the age-adjusted odds ratio for the development of 
epilepsy is 2.5 for patients with a depressive disorder (9) and these figures have been confirmed by at 
least other three studies with an increased risk up to 7-times in selected cases (10-12).  All these data 
clearly suggest that either some patients with depression develop epilepsy as part of the “natural 
course” of the depressive disorder or that depression is a premorbid phase of some epileptic 
syndromes.  
Anxiety disorders 
 Data on anxiety disorders are less systematic than those on depression and this is due to a 
number of reasons including, the high prevalence of depression in epilepsy that can mask anxiety 
disorders, a common attitude among neurologists in considering anxiety as the natural consequence of 
having unpredictable seizures and the potential misdiagnosis between panic attacks and seizure-based 
phenomena like ictal fear. As already discussed in the context of depression, the few available studies 
suggest a uniformly increased prevalence of all anxiety disorders (13). Two US National surveys show 
that people with self-reported epilepsy are two times more likely to report a diagnosis of anxiety 
disorder than those without (14, 15). These figures have been replicated by another cross-sectional, 
population-based study in unselected patients with epilepsy using standardised clinical interviews (16). 
Although less established as compared to depression, a few preliminary studies are suggesting a similar 
bidirectional relationship between epilepsy and anxiety disorders. A US study in veterans older than 65 
show that a previous history of anxiety is significantly more common in those who developed epilepsy as 
compared to controls (17). A population-based, case control study in Sweden show that patients 
hospitalised for anxiety disorders are more than 2 times at increased risk of developing unprovoked 
seizures (9). Finally a cohort study using data from the UK General Practice Research Database show that 
the incidence for anxiety disorders is not only higher in people with epilepsy as compared to controls 
but it is already increased three years prior to the diagnosis of epilepsy (8).  
 
Psychoses 
Psychoses and thought disorders are less frequent than mood and anxiety disorders but they 
represent serious complications affecting prognosis, morbidity and mortality in epilepsy. In general 
terms, epidemiological studies show that the prevalence of psychoses is 7 times higher than that of 
schizophreniform disorders in the general population (18). Psychotic symptoms in epilepsy are well 
recognised in a number of different clinical scenarios, from post-ictal psychoses (19), to antiepileptic-
drug related psychotic episodes (20), to chronic schizophrenia-like disorders (21). The prevalence of 
psychoses in epilepsy seems again related to the severity of the seizure disorder but also to the degree 
of pathology of the temporo-limbic structures.  Cross-sectional, population-based studies in unselected 
samples show that the prevalence of non-organic, non-affective psychoses, including schizophrenia and 
related disorders, is around 4%-5% (9, 22) but in selected samples, such as hospital case series, is even 
higher than that (23).  A systematic review and meta-analysis of published literature pointed out that 
patients with temporal lobe epilepsy present with the highest prevalence, in the region of 7% (24). In 
patients with temporal lobe epilepsy, those with febrile seizures and hippocampal sclerosis are more 
likely to develop psychoses than those with normal or minimal changes at the MRI (25). Interestingly, 
both a family history of psychoses and a family history of epilepsy have been identified as potential risk 
factors suggesting a strong neurobiological connection between epilepsy and psychoses [18]. As already 
discussed in the context of depression, psychoses have also shown a bidirectional relationship with 
epilepsy. A case-control study in Sweden shows that the age-adjusted odds ratio for seizures is 2.5 in 
patients with any diagnosis of psychosis even after controlling for antipsychotic drug treatment and 
other potential confounding factors (9). Two retrospective cohort studies show that patients with 
schizophrenia have a 2 to 3 times increased risk to develop epilepsy (26) with incidence rates of 7 per 
1000 person-year (27). 
Cognitive problems 
Cognitive problems represent a significant burden for any neurological disorder. Despite the 
large amount of epidemiological studies in children with epilepsy, there are no population-based studies 
investigating the neuropsychological status of people with adult-onset epilepsy (28). This obviously 
represents a serious omission in the scientific literature as the issue of cognitive problems is not just for 
children and young people but also for adults. In fact, a subjective impairment in cognitive functions is 
frequently reported by adult patients and ranging between 44% and 59% (29). Most importantly, 63% of 
patients perceive that antiepileptic drugs prevent them from achieving goals in life rather the epilepsy 
itself (30). The problem of neuropsychological deficits in adult-onset epilepsies is quite complex. Several 
studies have clearly shown that subjective memory complaints do not correlate with formal 
neuropsychological deficits but are rather due to other factors, especially anxiety and depression (31, 
32). Antiepileptic drugs have a different propensity for cognitive side effects but a number of different 
variables, which are both patient-related and epilepsy-related, have to be taken into account in adults 
(30).  
Patients are often concerned that the epilepsy may be responsible of accelerated brain aging. 
Although population-based studies in this area are lacking, it has been suggested that the potential 
cognitive decline in aging patients with epilepsy is very slow and the cognitive performance at the onset 
of the epilepsy is the most important variable (28, 33). It has been suggested that people with epilepsy 
may reach a clinically significant threshold of impairment late in life because they start at a lower 
baseline cognitive level than healthy subjects rather than because of a true accelerated cognitive decline 
(33). This would be further supported by studies in newly diagnosed adult patients with epilepsy 
showing that they are cognitively compromised even at the onset of the disorder and before starting 
antiepileptic drug treatment (34). Further studies in this area are urgently needed.   
 
Psychiatric comorbidities as a poor prognostic marker in adults with epilepsy 
The amount of epidemiological data on psychiatric comorbidities of epilepsy has increased the 
attention of clinicians and researchers on the potential impact of comorbidities on the prognosis of 
epilepsy and the identification of potential biomarkers (35). As already discussed, the different 
prevalence rates in different epilepsy populations, namely seizure free and drug-resistant patients, 
seems to suggest that the presence of psychiatric comorbidities partially reflects the severity of the 
seizure disorder. In adults with epilepsy, there is now enough literature supporting the hypothesis that 
psychiatric comorbidities represent also a poor prognostic marker.  
It has been established long time ago that depression is a better indicator of quality of life than 
seizure frequency itself (36). It is now becoming evident that depression is also associated with poor 
response to the antiepileptic drug treatment (37, 38), poor outcome after epilepsy surgery (39, 40), 
increased seizure severity (41), increased risk of injury (42) and premature mortality (43). Future studies 
need to clarify whether early identification and prompt treatment of psychiatric comorbidities can have 
an impact on the prognosis of the epilepsy or whether they just represent indicators of poor prognosis. 
 
COMORBIDITIES IN PEDIATRICS 
Psychiatric comorbidity has historically been less well studied in pediatrics than in adults.  
However, recent high quality population studies offer detailed information regarding the amount of 
medical and psychiatric comorbidity in pediatric epilepsy.  A recent study of a Norwegian patient registry 
showed that 78.3% of the pediatric epilepsy population had comorbid medical, neurologic or psychiatric 
illness as compared to 30.3% of the general pediatric population (44).  Developmental or psychiatric 
disorders were present in 42.9% of children with epilepsy, and higher if the epilepsy was deemed 
complicated.  Although the diagnoses were not verifiable beyond the initial medical record notation, the 
sample size of over one million is notable and reinforces the notion that psychiatric comorbidity is 
significant in the large population of persons with epilepsy. 
Sizeable comorbidity has also been found in a large scale retrospective study of newly diagnosed 
epilepsy.  Administrative review of over six million records found 7654 children with newly diagnosed 
epilepsy.  Neurobehavioral comorbidities were present in 60% of these children as compared to 23% 
without epilepsy (45).  These recent studies complement existing information in the adult population 
and affirm that comorbidity is markedly present in children as well as in adults.  Furthermore, in 
children, the comorbidity may be more readily measurable and thus stimulate valuable insight into 
theories of pathophysiologic overlap.   
Behavioral Side Effects of Anticonvulsants 
A common question, especially in children, is whether anticonvulsants cause behavioral or 
cognitive side effects.  Cognitive side effects may be more noticeable in children because of academic 
emphases and measurable trajectories of cognitive development.  Much literature in epilepsy has been 
devoted to potential side effects of anticonvulsant drugs, and despite the difficulty in isolating 
etiologies; some medicines have been nevertheless identified as more likely associated with behavioral 
issues (46).   
Behavioral side effects may be reported with any anticonvulsant, but depression and fatigue 
have commonly been associated with phenobarbital (47).  A recent retrospective review suggests that 
levetiracetam and valproate have behavioral side effects more often than other anticonvulsants, 
particularly if hyperactivity is noted at baseline (48).   
It must also be noted that anticonvulsant drugs often have positive effects upon behavior, 
particularly in the context of mood disorders, and have proven effective either as primary or adjunct 
treatments (49).  The conundrum of anticonvulsants yielding behavioral or cognitive side effects while at 
the same time serving as a valuable treatment option is still present.   
Childhood Absence Epilepsy (CAE) 
Childhood Absence Epilepsy (CAE) is characterized by interruptions in consciousness though 
with little other visible semiology.  Inattention is obvious during the seizures themselves, but also has 
long been observed in these children in between absence episodes.  One study of CAE comorbidity 
found that 25% had subtle cognitive deficits, 43% linguistic difficulties, and 61% had a psychiatric illness, 
primarily ADHD (50).  Differentiation of CAE from the inattentive subtype of Attention Deficit 
Hyperactivity Disorder may be difficult (51).   
For many years, CAE was considered a benign form of epilepsy, having little sequelae beyond 
the distraction associated with the discrete events.  However, if this were the case, then comorbidities 
of attention or executive function deficits would not be markedly overrepresented as compared to the 
typical pediatric population.   Instead, the cognitive deficits associated with CAE may be similar to those 
associated with Attention Deficit Hyperactivity Disorder in children without epilepsy (52).  CAE has 
increasingly become viewed as a disease with persisting cognitive problems, well beyond the time scale 
of individual absence episodes (53).  
The idea that attention and cognitive problems are so prominent in CAE suggests physiologic 
overlap of cognition and the mechanisms that underlie absence seizures.  An intriguing study recently 
done with fMRI suggests that connectivity in attention, salience, and default mode networks, are altered 
in CAE (54).  The consideration is that these network abnormalities persist beyond discrete seizure 
episodes and may explain the problems of executive function commonly seen in CAE.  Network 
abnormalities in epilepsy as well as in psychiatric disorders in general may explain a great deal of the 
overlap, not only with CAE, but with other epilepsies as well.  CAE is not just associated with attention or 
cognitive problems, but may involve mood complications as well (55).  The widespread networks 
subsuming generalized epilepsy may intuitively explain comorbidities present, even in a pediatric 
population (56). 
Mood disorder and Anxiety 
Mood disorder and anxiety often co-occur in children and adolescents without epilepsy.  Co-
occurrence of mood and anxiety disorders and epilepsy is likely to be as common in pediatrics as it is in 
adults, although large scale prospective studies addressing this comorbidity have not been done (57).  
Some studies in selected populations suggest co-occurrences of 5-40%, though samples are 
heterogeneous and assessment tools are variable (58-61).  Depression is underreported in pediatrics in 
general, and the same may be true in pediatric epilepsy (62, 63).   Many with depressive symptoms do 
not seek mental health treatment for reasons of stigma or lack of clinician availability (64). Clinically, 
quality of life measures have highlighted the adverse effect of depression in pediatric epilepsy.  Similar 
to adults, the presence of depression has a marked effect upon quality of life and upon recovery post-
surgery (65, 66). 
The association of depression or anxiety with specific seizure types or localization is less well 
established.  However, two small studies suggest that depression is more often present in children with 
temporal lobe seizure localization (67, 68).  This finding is consistent with literature associating 
depressive phenomena with temporal lobe pathology in persons without epilepsy (69).   
Attention Deficit Hyperactivity Disorder (ADHD)  
ADHD has proven to be very common in children with epilepsy.   Reports estimate that 30% of 
children with epilepsy may meet criteria for ADHD, with some reports suggesting prevalence up to 80% 
(70-72).  Both epilepsy and ADHD have problematic effects upon quality of life.  A recent report suggests 
that each condition is significantly detrimental to quality of life, and in combination, the adverse effects 
upon quality of life may be additive (73). 
It is still unclear as to which epilepsy characteristics are related to the presence of ADHD.  One 
preliminary report suggests that attention problems are more common with localization related epilepsy 
than with primary generalized epilepsy, but the sample was somewhat skewed and psychiatric 
diagnoses were not obtained at baseline (74).  Another study found that 80% of children with frontal 
lobe  sustained abnormal discharges on EEG also met criteria for ADHD (75). 
Several reports suggest that EEG abnormalities may be present in children with ADHD even 
without confirmed epilepsy (76, 77).  One report found that treatment with valproate improved 
paroxysmal EEG abnormalities as well as ADHD ratings (78).  The overlap may not be coincidental as a 
recent population study suggests that a bidirectional relationship is present between the two 
conditions.  The presence of either ADHD or epilepsy increased the odds for the subsequent 
development of the other condition (79).  
Autism Spectrum Disorders  
The overlap between epilepsy and intellectual and developmental disabilities has been 
frequently reported.  Epilepsy may be present in half of children and adolescents with autism or other 
developmental disorders (80).  Family studies also show overrepresentations of EEG abnormalities in 
persons with family histories of both autism and epilepsy (81).  Autism spectrum disorders are 
characterized by atypical communication, deficits in social reciprocity and stereotyped or narrow ranges 
of behaviors or activities.  Some epilepsy syndromes such as Landau Kleffner Syndrome, include irregular 
communication styles or atypical social pragmatic language, similar to what is present in autism (82).   
Ultimately the overlap may be physiologic in nature.  Some evidence suggests that neuronal 
hyperexcitability may be present in autism spectrum disorders.  Epileptiform abnormalities have been 
reported in autism, in the absence of clinically evident seizures (83).  Such neuronal hyperexcitability 
would be expected in seizure disorders and its presence in autism could reflect common 
pathophysiology between the two conditions.   One study suggests that a deficit in interneurons 
mediating the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) may be at fault in autism 
(84).  Such deficits in inhibition would be intuitive in epilepsy, which is in one sense, a disorder involving 
dysregulated neurons that activate inappropriately (85).   
Conclusion 
The weight of the evidence, regardless of heterogeneity in sampling or disagreements about 
ideal assessment techniques, clearly affirms that psychiatric comorbidity is a significant problem.  Details 
about bidirectionality, etiology or the possible existence of common pathophysiology are important, but 
the most important aspect may be the fact that these debates exist at all.  The discourse itself results in 
part from the still underappreciated notion that psychiatric conditions are associated with epilepsy more 
often than expected.   
Ultimately, medical care and treatment decisions relate to quality of life.  Quality of life may 
necessitate bold approaches to treatment.  Neurologists are the key directors of epilepsy care and as 
such, have no choice but to become competent in knowledge of psychiatry.  For persons with epilepsy, 
psychiatric comorbidity appears to be the rule rather than the exception, and as such, comprehensive 
care demands attention to mental health.   
 
References: 
1.  Josephson CB, Jette N. Psychiatric comorbidities in epilepsy. Int Rev Psychiatry. 2017;29:409-424. 
2.  Hermann BP, Vickrey B, Hays RD, Cramer J, Devinsky O, Meador K, Perrine K, Myers LW, Ellison GW. A 
comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. 
Epilepsy Res. 1996;25:113-118. 
3.  Jones JE, Siddarth P, Almane D, Gurbani S, Hermann BP, Caplan R. Identification of risk for severe 
psychiatric comorbidity in pediatric epilepsy. Epilepsia. 2016;57:1817-1825. 
4.  Hesdorffer DC, Baldin E, Caplan R, Berg AT. How do we measure psychiatric diagnoses? Implications 
of the choice of instruments in epilepsy. Epilepsy Behav. 2014;31:351-355. 
5.  Jacoby A, Baker GA, Steen N, Potts P, W CD. The clinical course of epilepsy and its psychosocial 
correlates: Findings from a U.K. community study. Epilepsia. 1996;37:708-715. 
6.  Tellez-Zenteno JF, Patten SB, Jette N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a 
population-based analysis. Epilepsia. 2007;48:2336-2344. 
7.  Gilliam FG, Santos J, Vahle V, Carter J, Brown K, Hecimovic H. Depression in epilepsy: ignoring clinical 
expression of neuronal network dysfunction? Epilepsia. 2004;45 Suppl 2:28-33. 
8.  Hesdorffer DC, Ishihara L, Mynepalli L, Webb DJ, Weil J, Hauser WA. Epilepsy, suicidality, and 
psychiatric disorders: a bidirectional association. Ann Neurol. 2012;72:184-191. 
9.  Adelow C, Andersson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders before and 
after onset of unprovoked seizures/epilepsy. Neurology. 2012;78:396-401. 
10.  Forsgren L, Nystrom L. An incident case-referent study of epileptic seizures in adults. Epilepsy Res. 
1990;6:66-81. 
11.  Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in 
older adults. Ann Neurol. 2000;47:246-249. 
12.  Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O. Depression and suicide attempt 
as risk factors for incident unprovoked seizures. Ann Neurol. 2006;59:35-41. 
13.  Brandt C, Mula M. Anxiety disorders in people with epilepsy. Epilepsy Behav. 2016;59:87-91. 
14.  Kobau R, Gilliam F, Thurman DJ. Prevalence of self-reported epilepsy or seizure disorder and its 
associations with self-reported depression and anxiety: results from the 2004 HealthStyles Survey. 
Epilepsia. 2006;47:1915-1921. 
15.  Ottman R, Lipton RB, Ettinger AB, Cramer JA, Reed ML, Morrison A, Wan GJ. Comorbidities of 
epilepsy: results from the Epilepsy Comorbidities and Health (EPIC) survey. Epilepsia. 2011;52:308-315. 
16.  Rai D, Kerr MP, McManus S, Jordanova V, Lewis G, Brugha TS. Epilepsy and psychiatric comorbidity: 
a nationally representative population-based study. Epilepsia. 2012;53:1095-1103. 
17.  Ettinger AB, Copeland LA, Zeber JE, Van Cott AC, Pugh MJ. Are psychiatric disorders independent risk 
factors for new-onset epilepsy in older individuals? Epilepsy Behav. 2010;17:70-74. 
18.  Kanner AM, Rivas-Grajales AM. Psychosis of epilepsy: a multifaceted neuropsychiatric disorder. CNS 
Spectr. 2016;21:247-257. 
19.  Adachi N, Ito M, Kanemoto K, Akanuma N, Okazaki M, Ishida S, Sekimoto M, Kato M, Kawasaki J, 
Tadokoro Y, Oshima T, Onuma T. Duration of postictal psychotic episodes. Epilepsia. 2007;48:1531-1537. 
20.  Chen Z, Lusicic A, O'Brien TJ, Velakoulis D, Adams SJ, Kwan P. Psychotic disorders induced by 
antiepileptic drugs in people with epilepsy. Brain. 2016;139:2668-2678. 
21.  Adachi N, Matsuura M, Okubo Y, Oana Y, Takei N, Kato M, Hara T, Onuma T. Predictive variables of 
interictal psychosis in epilepsy. Neurology. 2000;55:1310-1314. 
22.  Qin P, Xu H, Laursen TM, Vestergaard M, Mortensen PB. Risk for schizophrenia and schizophrenia-
like psychosis among patients with epilepsy: population based cohort study. BMJ. 2005;331:23. 
23.  Mendez MF, Grau R, Doss RC, Taylor JL. Schizophrenia in epilepsy: seizure and psychosis variables. 
Neurology. 1993;43:1073-1077. 
24.  Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR. The prevalence of psychosis in epilepsy; a 
systematic review and meta-analysis. BMC Psychiatry. 2014;14:75. 
25.  Kanemoto K, Takeuchi J, Kawasaki J, Kawai I. Characteristics of temporal lobe epilepsy with mesial 
temporal sclerosis, with special reference to psychotic episodes. Neurology. 1996;47:1199-1203. 
26.  Wotton CJ, Goldacre MJ. Coexistence of schizophrenia and epilepsy: record-linkage studies. 
Epilepsia. 2012;53:e71-74. 
27.  Chang YT, Chen PC, Tsai IJ, Sung FC, Chin ZN, Kuo HT, Tsai CH, Chou IC. Bidirectional relation 
between schizophrenia and epilepsy: a population-based retrospective cohort study. Epilepsia. 
2011;52:2036-2042. 
28.  Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the 
lifespan. Lancet. 2012;380:1180-1192. 
29.  Meador KJ. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res. 2006;68:63-
67. 
30.  Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms 
and contributing factors. CNS Drugs. 2009;23:121-137. 
31.  Mula M, von Oertzen TJ, Cock HR, Lozsadi DA, Agrawal N. Clinical correlates of memory complaints 
during AED treatment. Acta Neurol Scand. 2016. 
32.  Marino SE, Meador KJ, Loring DW, Okun MS, Fernandez HH, Fessler AJ, Kustra RP, Miller JM, Ray PG, 
Roy A, Schoenberg MR, Vahle VJ, Werz MA. Subjective perception of cognition is related to mood and 
not performance. Epilepsy Behav. 2009;14:459-464. 
33.  Helmstaedter C, Elger CE. Chronic temporal lobe epilepsy: a neurodevelopmental or progressively 
dementing disease? Brain. 2009;132:2822-2830. 
34.  Taylor J, Kolamunnage-Dona R, Marson AG, Smith PE, Aldenkamp AP, Baker GA, group Ss. Patients 
with epilepsy: cognitively compromised before the start of antiepileptic drug treatment? Epilepsia. 
2010;51:48-56. 
35.  Ravizza T, Onat FY, Brooks-Kayal AR, Depaulis A, Galanopoulou AS, Mazarati A, Numis AL, Sankar R, 
Friedman A. WONOEP appraisal: Biomarkers of epilepsy-associated comorbidities. Epilepsia. 
2017;58:331-342. 
36.  Boylan LS, Flint LA, Labovitz DL, Jackson SC, Starner K, Devinsky O. Depression but not seizure 
frequency predicts quality of life in treatment-resistant epilepsy. Neurology. 2004;62:258-261. 
37.  Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ. Predictors of pharmacoresistant epilepsy. Epilepsy 
Res. 2007;75:192-196. 
38.  Nogueira MH, Yasuda CL, Coan AC, Kanner AM, Cendes F. Concurrent mood and anxiety disorders 
are associated with pharmacoresistant seizures in patients with MTLE. Epilepsia. 2017;58:1268-1276. 
39.  Kanner AM, Byrne R, Chicharro A, Wuu J, Frey M. A lifetime psychiatric history predicts a worse 
seizure outcome following temporal lobectomy. Neurology. 2009;72:793-799. 
40.  Koch-Stoecker SC, Bien CG, Schulz R, May TW. Psychiatric lifetime diagnoses are associated with a 
reduced chance of seizure freedom after temporal lobe surgery. Epilepsia. 2017;58:983-993. 
41.  Cramer JA, Blum D, Reed M, Fanning K. The influence of comorbid depression on seizure severity. 
Epilepsia. 2003;44:1578-1584. 
42.  Gur-Ozmen S, Mula M, Agrawal N, Cock HR, Lozsadi D, von Oertzen TJ. The effect of depression and 
side effects of antiepileptic drugs on injuries in patients with epilepsy. Eur J Neurol. 2017;24:1135-1139. 
43.  Fazel S, Wolf A, Langstrom N, Newton CR, Lichtenstein P. Premature mortality in epilepsy and the 
role of psychiatric comorbidity: a total population study. Lancet. 2013;382:1646-1654. 
44.  Aaberg KM, Bakken IJ, Lossius MI, Lund Soraas C, Haberg SE, Stoltenberg C, Suren P, Chin R. 
Comorbidity and Childhood Epilepsy: A Nationwide Registry Study. Pediatrics. 2016;138. 
45.  Oh A, Thurman DJ, Kim H. Comorbidities and risk factors associated with newly diagnosed epilepsy 
in the U.S. pediatric population. Epilepsy Behav. 2017;75:230-236. 
46.  Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, Aldenkamp AP, Steinhoff BJ. Epilepsy, 
Antiepileptic Drugs, and Aggression: An Evidence-Based Review. Pharmacol Rev. 2016;68:563-602. 
47.  Salpekar JA, Mishra G, Hauptman AJ. Key issues in addressing the comorbidity of depression and 
pediatric epilepsy. Epilepsy Behav. 2015;46:12-18. 
48.  Guilfoyle SM, Follansbee-Junger K, Smith AW, Combs A, Ollier S, Hater B, Modi AC. Antiepileptic 
drug behavioral side effects and baseline hyperactivity in children and adolescents with new onset 
epilepsy. Epilepsia. 2018;59:146-154. 
49.  Davico C, Canavese C, Vittorini R, Gandione M, Vitiello B. Anticonvulsants for Psychiatric Disorders in 
Children and Adolescents: A Systematic Review of Their Efficacy. Frontiers in psychiatry. 2018;9:270. 
50.  Caplan R, Siddarth P, Stahl L, Lanphier E, Vona P, Gurbani S, Koh S, Sankar R, Shields WD. Childhood 
absence epilepsy: Behavioral, cognitive, and linguistic comorbidities. Epilepsia. 2008. 
51.  Salpekar JA, Mishra G. Key Issues in Addressing the Comorbidity of Attention Deficit Hyperactivity 
Disorder and Pediatric Epilepsy. Epilepsy Behav. 2014. 
52.  Lee HJ, Kim EH, Yum MS, Ko TS, Kim HW. Attention profiles in childhood absence epilepsy compared 
with attention-deficit/hyperactivity disorder. Brain Dev. 2018;40:94-99. 
53.  Verrotti A, Matricardi S, Rinaldi VE, Prezioso G, Coppola G. Neuropsychological impairment in 
childhood absence epilepsy: Review of the literature. J Neurol Sci. 2015;359:59-66. 
54.  Li Q, Cao W, Liao X, Chen Z, Yang T, Gong Q, Zhou D, Luo C, Yao D. Altered resting state functional 
network connectivity in children absence epilepsy. J Neurol Sci. 2015;354:79-85. 
55.  Vega C, Guo J, Killory B, Danielson N, Vestal M, Berman R, Martin L, Gonzalez JL, Blumenfeld H, 
Spann MN. Symptoms of anxiety and depression in childhood absence epilepsy. Epilepsia. 2011;52:e70-
74. 
56.  Scharfman HE, Kanner AM, Friedman A, Blumcke I, Crocker CE, Cendes F, Diaz-Arrastia R, Forstl H, 
Fenton AA, Grace AA, Palop J, Morrison J, Nehlig A, Prasad A, Wilcox KS, Jette N, Pohlmann-Eden B. 
Epilepsy as a Network Disorder (2): What can we learn from other network disorders such as dementia 
and schizophrenia, and what are the implications for translational research? Epilepsy Behav. 2017. 
57.  Reilly C, Agnew R, Neville BG. Depression and anxiety in childhood epilepsy: a review. Seizure. 
2011;20:589-597. 
58.  Maryam S, Parviz B. Depression in children and adolescents with epilepsy: a 15 year research review 
of prevalence, and demographic and seizure related correlates. Iranian journal of pediatrics. 2013;23:1-
7. 
59.  Han SH, Lee SA, Eom S, Kim HD, Korean Qo LiESG. Family factors contributing to emotional and 
behavioral problems in Korean adolescents with epilepsy. Epilepsy Behav. 2016;56:66-72. 
60.  Liu X, Han Q. Depression and anxiety in children with benign childhood epilepsy with 
centrotemporal spikes (BCECTS). BMC Pediatr. 2016;16:128. 
61.  Roeder R, Roeder K, Asano E, Chugani HT. Depression and mental health help-seeking behaviors in a 
predominantly African American population of children and adolescents with epilepsy. Epilepsia. 
2009;50:1943-1952. 
62.  Coyle JT, Pine DS, Charney DS, Lewis L, Nemeroff CB, Carlson GA, Joshi PT, Reiss D, Todd RD, 
Hellander M, Depression, Bipolar Support Alliance Consensus Development P. Depression and bipolar 
support alliance consensus statement on the unmet needs in diagnosis and treatment of mood 
disorders in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2003;42:1494-1503. 
63.  Dunn DW, Besag F, Caplan R, Aldenkamp A, Gobbi G, Sillanpaa M. Psychiatric and Behavioural 
Disorders in Children with Epilepsy (ILAE Task Force Report): Anxiety, depression and childhood epilepsy. 
Epileptic Disord. 2016. 
64.  Vona P, Siddarth P, Sankar R, Caplan R. Obstacles to mental health care in pediatric epilepsy: insight 
from parents. Epilepsy Behav. 2009;14:360-366. 
65.  Hamid H, Blackmon K, Cong X, Dziura J, Atlas LY, Vickrey BG, Berg AT, Bazil CW, Langfitt JT, Walczak 
TS, Sperling MR, Shinnar S, Devinsky O. Mood, anxiety, and incomplete seizure control affect quality of 
life after epilepsy surgery. Neurology. 2014;82:887-894. 
66.  Puka K, Smith ML. Predictors of long-term quality of life after pediatric epilepsy surgery. Epilepsia. 
2015;56:873-881. 
67.  Salpekar JA, Berl MM, Havens K, Cushner-Weinstein S, Conry JA, Pearl PL, Yaun AL, Gaillard WD. 
Psychiatric symptoms in children prior to epilepsy surgery differ according to suspected seizure focus. 
Epilepsia. 2013;54:1074-1082. 
68.  Pereira A, Valente KD. Severity of depressive symptomatology and functional impairment in children 
and adolescents with temporal lobe epilepsy. Seizure. 2013;22:708-712. 
69.  Caetano SC, Fonseca M, Hatch JP, Olvera RL, Nicoletti M, Hunter K, Lafer B, Pliszka SR, Soares JC. 
Medial temporal lobe abnormalities in pediatric unipolar depression. Neurosci Lett. 2007;427:142-147. 
70.  Besag F, Gobbi G, Caplan R, Sillanpaa M, Aldenkamp A, Dunn DW. Psychiatric and Behavioural 
Disorders in Children with Epilepsy (ILAE Task Force Report): Epilepsy and ADHD. Epileptic Disord. 2016. 
71.  Cohen R, Senecky Y, Shuper A, Inbar D, Chodick G, Shalev V, Raz R. Prevalence of epilepsy and 
attention-deficit hyperactivity (ADHD) disorder: a population-based study. J Child Neurol. 2013;28:120-
123. 
72.  Torres AR, Whitney J, Gonzalez-Heydrich J. Attention-deficit/hyperactivity disorder in pediatric 
patients with epilepsy: review of pharmacological treatment. Epilepsy Behav. 2008;12:217-233. 
73.  Ekinci O, Okuyaz C, Erdogan S, Gunes S, Ekinci N, Kalinli M, Teke H, Direk MC. Attention-Deficit 
Hyperactivity Disorder (ADHD) in Epilepsy and Primary ADHD: Differences in Symptom Dimensions and 
Quality of Life. J Child Neurol. 2017;32:1083-1091. 
74.  Gascoigne MB, Smith ML, Barton B, Webster R, Gill D, Lah S. Attention deficits in children with 
epilepsy: Preliminary findings. Epilepsy Behav. 2017;67:7-12. 
75.  Zhang DQ, Li FH, Zhu XB, Sun RP. Clinical Observations on Attention-Deficit Hyperactivity Disorder 
(ADHD) in Children With Frontal Lobe Epilepsy. J Child Neurol. 2012. 
76.  Silvestri R, Gagliano A, Calarese T, Arico I, Cedro C, Condurso R, Germano E, Vita G, Tortorella G. Ictal 
and interictal EEG abnormalities in ADHD children recorded over night by video-polysomnography. 
Epilepsy Res. 2007;75:130-137. 
77.  Fonseca LC, Tedrus GM, Moraes C, Vicente Machado A, Almeida MP, Oliveira DO. Epileptiform 
abnormalities and quantitative EEG in children with attention-deficit/hyperactivity disorder. Arq 
Neuropsiquiatr. 2008;66:462-467. 
78.  Kanemura H, Sano F, Tando T, Hosaka H, Sugita K, Aihara M. EEG improvements with antiepileptic 
drug treatment can show a high correlation with behavioral recovery in children with ADHD. Epilepsy 
Behav. 2013;27:443-448. 
79.  Chou IC, Chang YT, Chin ZN, Muo CH, Sung FC, Kuo HT, Tsai CH, Kao CH. Correlation between 
epilepsy and attention deficit hyperactivity disorder: a population-based cohort study. PLoS One. 
2013;8:e57926. 
80.  Sillanpaa M, Besag F, Aldenkamp A, Caplan R, Dunn DW, Gobbi G. Psychiatric and Behavioural 
Disorders in Children with Epilepsy (ILAE Task Force Report): Epidemiology of psychiatric/behavioural 
disorder in children with epilepsy. Epileptic Disord. 2016. 
81.  Ekinci O, Arman AR, Isik U, Bez Y, Berkem M. EEG abnormalities and epilepsy in autistic spectrum 
disorders: clinical and familial correlates. Epilepsy Behav. 2010;17:178-182. 
82.  Wheless JW, Simos PG, Butler IJ. Language dysfunction in epileptic conditions. Semin Pediatr Neurol. 
2002;9:218-228. 
83.  Trauner DA. Behavioral correlates of epileptiform abnormalities in autism. Epilepsy Behav. 
2015;47:163-166. 
84.  Jacob J. Cortical interneuron dysfunction in epilepsy associated with autism spectrum disorders. 
Epilepsia. 2016;57:182-193. 
85.  Salpekar J. Neuropsychiatric effects of epilepsy in developmental disorders. Current opinion in 
psychiatry. 2018;31:109-115. 
 
